Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iforu
- Development stage
- Unknown
- Lead developer
- Centaur Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Iforu (also known as I for U) is an oral nutritional supplement and hematinic developed by Centaur Pharmaceuticals. It is formulated as a combination of iron (in forms such as ferric pyrophosphate, ferric ammonium citrate, or ferrous ascorbate) and the amino acid glycine. Iforu is approved for the treatment and prevention of iron deficiency, iron deficiency anemia, and associated nutritional deficiencies, particularly in pediatric populations and during pregnancy. The combination of iron with glycine forms a chelated structure that enhances iron absorption and bioavailability while minimizing common gastrointestinal side effects such as constipation and stomach upset.
- Brand names
- I for UIFORU LiquidIforu
- Other names
- ferric ammonium citrate + glycineferric pyrophosphate + glycineferrous ascorbate + glycineiron + glycine
Beyond the preview
Go deeper on Iforu.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Iforu.